1.Medical Education in Australia
Kazuo SHIZUME ; Michio OKAJIMA ; Akira AKAIKE ; Noboru KOBAYASHI ; Takashi WAGATSUMA ; Tetsuya AKAGAWA
Medical Education 1971;2(4):259-270
2.Effects of combined therapy of alendronate and low-intensity pulsed ultrasound on metaphyseal bone repair after osteotomy in the proximal tibia of glucocorticoid-induced osteopenia rats.
Tetsuya KAWANO ; Naohisa MIYAKOSHI ; Yuji KASUKAWA ; Michio HONGO ; Hiroyuki TSUCHIE ; Chie SATO ; Masashi FUJII ; Masazumi SUZUKI ; Manabu AKAGAWA ; Yuichi ONO ; Yusuke YUASA ; Itsuki NAGAHATA ; Yoichi SHIMADA
Osteoporosis and Sarcopenia 2017;3(4):185-191
OBJECTIVES: Glucocorticoid (GC) treatment inhibits activation of runt-related transcription factor 2 (Runx2), which is essential for osteoblast differentiation from stem cells. As a result, GC treatment results in bone loss, GC-induced osteoporosis (GIO), elevated fracture risk, and delayed bone healing. Bisphosphonates such as alendronate (ALN) are recommended for treating or preventing GIO, and lowintensity pulsed ultrasound (LIPUS) facilitates fracture healing and maturation of regenerated bone. Combined therapy with ALN and LIPUS may stimulate cancellous bone healing in GIO rats. Here, we examined the effect of ALN and LIPUS on cancellous bone osteotomy repair in the proximal tibia of GIO rats. METHODS: Prednisolone (10 mg/kg body weight/day) was administered for 4 weeks to induce GIO in 6-month-old female Sprague-Dawley rats. Tibial osteotomy was then performed and daily subcutaneous injection of ALN (1-µg/kg body weight) was subsequently administered alone or in combination with LIPUS (20 min/day) for 2 or 4 weeks. RESULTS: ALN significantly increased bone mineral density (BMD) at 2 and 4 weeks, and ALN + LIPUS significantly increased BMD at 4 weeks. Bone union rates were significantly increased after 2 and 4 weeks ALN and ALN + LIPUS treatment. Lastly, ALN and ALN + LIPUS significantly increased the proportion of Runx2 positive cells at 4 weeks. CONCLUSIONS: ALN monotherapy and combined ALN and LUPUS treatment augmented BMD and stimulated cancellous bone repair with increased Runx2 expression at the osteotomy site in GIO rats. However, the combined treatment had no additional effect on cancellous bone healing compared to ALN monotherapy.
Alendronate*
;
Animals
;
Bone Density
;
Bone Diseases, Metabolic*
;
Diphosphonates
;
Female
;
Fracture Healing
;
Humans
;
Infant
;
Injections, Subcutaneous
;
Osteoblasts
;
Osteoporosis
;
Osteotomy*
;
Prednisolone
;
Rats*
;
Rats, Sprague-Dawley
;
Stem Cells
;
Tibia*
;
Transcription Factors
;
Ultrasonic Waves*
3.Development of a Training Program on the Proper Use of Over-the-Counter Drugs for Pharmacy Pharmacists
Chie HIRAOKA ; Keiko (Sasaki) AKAGAWA ; Yoshiaki FUJITA ; Yuki ODANAKA ; Atsuhiko SANO ; Mika NAGANUMA ; Tetsuya OGINO ; Hajime KATO ; Akihiro NAKAMURA
Japanese Journal of Social Pharmacy 2022;41(2):155-166
The importance of promoting self-medication is increasing, and the active participation of pharmacies is required to support this. We developed a training program based on the Attention, Relevance, Confidence, and Satisfaction (ARCS) model, which is a motivational design process to train pharmacists who support the proper use of OTC drugs, and for insurance pharmacists who usually perform dispensing work. In the six months of training, we conducted six sessions for insurance pharmacists on the subject of colds and constipation. In addition to conducting lectures and exercises on OTC drugs, we provided pharmacists with an opportunity to practice the training content during their daily work, and discuss solutions to the problems that they encountered. Of the eight participants who attended all workshops and were part of the final evaluation, seven provided OTC drugs after considering whether it was necessary to provide them. A total of six advised patients who came to the pharmacy to have their prescription medications dispensed that there were OTC medications that they should be careful about taking. These results suggest the usefulness of this training program based on the ARCS motivational design model.